MRNA240816P122000
- 40.89
- 0.000.00%
Moderna Newsroom
Struggling COVID-19 Vaccines From AstraZeneca, BioNTech/Pfizer, Moderna Cut Incidence Of Arterial Thromboses That Cause Heart Attacks, Strokes, British Study Shows
Long Covid Remains Diagnostic Mystery, Diagnosis Remains Elusive; National Institutes of Health-Funded Study Shows
Smart Money Is Betting Big In MRNA Options
Analyst Maintains Sell Rating on Moderna Amid Revenue Guidance Downgrade and Competitive Challenges
Express News | Africa CDC Declares Mpox A Public Health Emergency Of Continental Security
10 Health Care Stocks With Whale Alerts In Today's Session
Market Whales and Their Recent Bets on MRNA Options
The Rise of OpenAI and Microsoft's $13 Billion Bet on the AI Startup
Express News | Moderna : Leerink Partners Raises Target Price to $58 From $56
The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna
10 Health Care Stocks Whale Activity In Today's Session
Over 50% of the Nasdaq-100 Names Trade Below Their 200-day Moving Average
Express News | Africa CDC Plans To Declare Regional Mpox Outbreak An Emergency
Unusual Options Activity: GOLD, ARCC and Others Attract Market Bets, GOLD V/OI Ratio Reaches 166.7
What the Options Market Tells Us About Moderna
Deutsche Bank Upgrades Moderna to Hold From Sell, Adjusts Price Target to $80 From $85
Express News | Deutsche Bank Upgrades Moderna to Hold, Lowers Price Target to $80
When Product Launches Struggle, Biotech Investors Reward Cost Cuts -- WSJ
Moderna, Inc. (NASDAQ:MRNA) Analysts Are More Bearish Than They Used To Be
Express News | Arbutus Biopharma Corp - Requesting Amended Case Schedule to Accommodate Certain Outstanding Discovery From Moderna and Third Parties